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Abstract 26 
Mitochondrial DNA (mtDNA) variation has been implicated in many common complex 27 
diseases, but inconsistent and contradicting results are common. Here we introduce a novel 28 
mutational load hypothesis, which also considers the collective effect of mainly rare variants, 29 
utilising the MutPred Program. We apply this new methodology to investigate the possible 30 
role of mtDNA in two cardiovascular disease (CVD) phenotypes (hypertension and 31 
hyperglycaemia), within a two-population cohort (n = 363; mean age 45 ± 9 yrs.). Very few 32 
studies have looked at African mtDNA variation in the context of complex disease, and none 33 
using complete sequence data in a well-phenotyped cohort. As such, our study will also 34 
extend our knowledge of African mtDNA variation, with complete sequences of Southern 35 
Africans being especially under-represented. The cohort showed prevalence rates for 36 
hypertension (58.6%) and prediabetes (44.8%). We could not identify a statistically 37 
significant role for mtDNA variation in association with hypertension or hyperglycaemia in 38 
our cohort. However, we are of the opinion that the method described will find wide 39 
application in the field, being especially useful for cohorts from multiple locations or with a 40 
variety of mtDNA lineages, where the traditional haplogroup association method has been 41 
particularly likely to generate spurious results in the context of association with common 42 
complex disease.  43 
 44 
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1.  Introduction 49 
Cardiovascular disease (CVD) is an umbrella term that encompasses several distinctive 50 
disease phenotypes incisive of myocardial infarction, stroke, congenital heart disease and risk 51 
factors such as hypertension, and diabetes type 2 (Mensah, 2013). Discrepancies between 52 
different population groups exist in the onset, development and outcome of CVDs. (Okin et 53 
al., 2011; Moran et al., 2013; Owolabi et al., 2014). Although environmental and lifestyle 54 
factors play a role in the risk of developing CVD, genetic factors are likely to account for 55 
some of the observed discrepancies in CVD onset, and particularly progression/outcome of 56 
disease (Achilli et al., 2011). Nuclear DNA risk factors have not been able to account for all 57 
the observed inconsistencies among different population groups (Kaufman et al., 2015). Thus, 58 
other sources of variation, such as epigenetics and Mitochondrial DNA (mtDNA) variation 59 
might account for some of the missing heritability in CVDs.  60 
mtDNA mutations are a common cause of inherited disease (Gorman et al., 2015). Both 61 
diabetes and cardiomyopathy are frequent symptoms in primary mitochondrial disease 62 
(Taylor et al., 2003; Yarham et al., 2010), especially in patients with the mtDNA 63 
m.3243A>G mutation (Hollingsworth et al., 2012). While clinically manifesting mtDNA 64 
mutations are a recognised cause of human disease, many studies have suggested a role for 65 
common mtDNA variants (Hernstadt and Howell, 2004; Wallace, 2010) and the combined 66 
effect of rare population variants (Elson et al., 2006) in common complex disease. For CVDs 67 
specifically, a more recent Framingham Heart sub-study showed significant associations 68 
between several population as well as rare variants, and variation in blood pressure and 69 
fasting blood glucose levels (Lui et al., 2012). Cardena et al. (2014, 2016) found the 70 
hypertensive phenotype to be more prevalent among heart failure patients with an African 71 
mitochondrial haplogroup than among those with European haplogroups, in an admixed 72 
Brazilian cohort.    73 
Human mtDNA codes for 13 essential polypeptide components of the mitochondrial 74 
oxidative phosphorylation (OXPHOS) system. mtDNA undergoes strict maternal inheritance, 75 
resulting in the absence of bi-parental recombination (Elson et al., 2001) and has a high 76 
mutation rate (Tuppen et al., 2010). As such, the evolution of mtDNA is characterised by the 77 
emergence of distinct lineages (or haplogroups) (Hernstadt et al., 2002). This results in high 78 
levels of mtDNA variation at the population level despite its rather small size, which is also 79 
illustrated by the large number of sub-haplogroups (van Oven and Kayser, 2009). Africa 80 
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(haplogroups L0‒L6) has the highest levels of nuclear and mitochondrial genetic diversity 81 
(Salas et al., 2002);  this diversity was reduced by population bottlenecks in groups migrating 82 
from Africa (Manica et al., 2007). However, variation in African populations, especially in 83 
relation to disease, is still under studied when compared to variation in super clade N 84 
(Cavadas et al., 2015; Gurdasani et al., 2015). Only about 12% of mtDNA sequences on 85 
GenBank are of African lineages. In terms of mtDNA ancestry, the African haplogroup L3 86 
incorporates super clades M and N, which encompass all the European and Asian 87 
haplogroups (Hernstadt et al., 2002; van Oven and Kayser, 2009; Rosa and Brehem, 2011).   88 
Given the unique inheritance pattern of mtDNA, it is worth considering the hypothesis that 89 
might link mtDNA population variation to common complex disease. Firstly, studies showing 90 
significant associations of several disease phenotypes with specific mtDNA haplogroups have 91 
been published, suggesting that one or more common population variants may modify risk or 92 
outcome of disease. Secondly, the high mutation rate of mtDNA frequently results in the 93 
same variant being present more than once on the phylogeny (Hernstadt et al., 2002). 94 
Showing that such a variant modifies risk or alters the course of disease (Yu et al., 2008) in 95 
two different haplogroups or global populations, would be excellent evidence of it’s role in 96 
disease. The third possibility is that rare mtDNA mutations might have an effect, either at the 97 
individual level with there being synergist effects of multiple rare variants in patients, or rare 98 
variants might just be seen more frequently in the patient group. 99 
The first hypothesis mentioned above, known as the haplogroup association hypothesis, has 100 
to date been the classic approach to use when considering the role of mtDNA variation in 101 
common disease. These studies have been controversial due to their low repeatability; often 102 
the association is not detected in a second cohort, or an association with a different 103 
haplogroup might be uncovered (Salas and Elson, 2015). Some studies have taken a two-104 
cohort approach in an attempt to address these problems (Elson et al., 2006; Chinnery et al., 105 
2010). Even so, this approach has proved unsuitable for many studies with cohorts that do not 106 
have the large numbers required for well-powered haplogroup association studies (Samuels et 107 
al., 2006). 108 
In this study, we take an alternative approach, using MutPred pathogenicity scores to derive 109 
“mutational loads”. This is a new version of the “mutational load” hypothesis proposed by 110 
Elson et al. (2006), which looked at the frequency of mildly deleterious (rare) variants in 111 
patient and control groups, to test the possibility of a cumulative effect of these variants. 112 
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After calculating “MutPred mutational loads” by summing the MutPred scores generated for 113 
each of the non-synonymous variants on an individual’s mtDNA, we adjusted these for the 114 
position of the sequence in the phylogeny, ultimately calculating “MutPred adjusted loads”. 115 
Many different tools for predicting pathogenicity of mtDNA variants exist, but in a 116 
comparative study by Thusberg et al (2011), MutPred and SNPs&GO outperformed all other 117 
methods, which included PolyPhen2, SIFT and SNAP. The MutPred program has also been 118 
widely validated in the context of mtDNA variation (Pereira et al., 2011). The MutPred 119 
algorithm incorporates elements of the SIFT algorithm, and assigns a pathogenicity score 120 
between 0‒1, with zero being a benign substitution.  A pathogenic score above 0.5 can be 121 
considered an “actionable hypothesis”, while a score above 0.75 can be considered a 122 
“confident hypothesis” (Li et al., 2009). As there is selection against mildly deleterious 123 
variants at the population level (Elson et al., 2004; Soares et al., 2013), variants with MutPred 124 
scores above the “actionable hypothesis” threshold (0.5) are less likely to define major 125 
haplogroups; rather, they are more likely to be rare and seen on very recent branches (twigs) 126 
of the phylogeny (Pereira et al., 2011).  Because the number of low-scoring, low-impact 127 
common variant differs greatly among different population groups, their inclusion in the 128 
calculation of mutational loads could introduce noise that is unlikely to have phenotypic 129 
impact. By excluding variants with a pathogenicity score below 0.5, and thus most common 130 
population variants, before calculating MutPred adjusted loads, we aim to highlight the 131 
impact of rare variants while reducing the effect of population stratification.  132 
Although mtDNA variation involvement in CVDs have previously been investigated 133 
(Chinnery et al., 2010), these studies have been predominantly in Caucasian European 134 
populations. Very few such studies have been published on African populations or those of 135 
African descent, were mostly on small sized cohorts, and often focused on specific previously 136 
reported variants (Khogali et al., 2001; Robinson et al., 2004; Ameh et al., 2011). To assume 137 
that findings from studies in European populations can easily be extrapolated to less 138 
investigated, genetically diverse African population groups would be short sighted (van der 139 
Westhuizen et al., 2015), as even clinically proven disease causing mutations as well as the 140 
underlying spectrum of mutations are known to have differing impacts in Africans (van der 141 
Walt et al., 2012; van der Westhuizen et al., 2015). 142 
In this study, we used the two-population Sympathetic Activity and Ambulatory Blood 143 
Pressure in Africans (SABPA) cohort (Malan et al., 2015) (Table 1). This is a South African 144 
cohort which consisted of 409 Black and Caucasian South African participants from the same 145 
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geographical area (Rosa and Brehem, 2011; Salas and Elson, 2015). Although the 146 
participants were matched for gender, age and socio-economic status, a significantly higher 147 
percentage of Black participants, compared to Caucasians participants, with optimal blood 148 
pressure at the start of the study, developed hypertension within five years (Schutte et al., 149 
2012; Hamer et al., 2015). A wide range of clinical and phenotypical analysis data are 150 
available for this cohort, including the golden standard 24 hour ambulatory blood pressure 151 
monitoring (24 h ABPM) measurements and a measurement of hyperglycaemia (HbA1c, 152 
glycated haemoglobin), which are routinely used to identify hypertension and diabetes 153 
respectively in a clinical setup.  154 
Using this unique cohort, we aimed to determine if mtDNA variation, using the MutPred 155 
adjusted load as defining parameter, is different in those with hypertension or 156 
hyperglycaemia when compared to those without. As such, we present a new and updated 157 
method for attempting to associate mtDNA variation with a complex trait. This method 158 
would be applicable to all mtDNA association studies, and be less affected by population 159 
stratification. 160 
  161 
2. Results 162 
After some samples fall-out due to technicalities such as sample unavailability and 163 
insufficient DNA extraction, 194 participants with macro-haplogroup L (haplogroups L0‒L4) 164 
and 169 participants with macro-haplogroup MN (haplogroups M, N, R, B, H, I, J, K, T, U 165 
and W) were used in this study. In Table 1, some of the most important phenotypical 166 
measurements (age, body mass index, blood glucose levels and blood pressure) are 167 
summarised. Immediately, large differences in both systolic and diastolic 24 h ABPM 168 
measurements, as well as differences in blood glucose measurements, can be noted between 169 
different mtDNA background and gender groups (Fig. 1). For both blood pressure 170 
measurements (systolic and diastolic), haplogroup L males have significantly higher values 171 
than all other groups (P < 0.0001).  Haplogroup L females also had significantly higher blood 172 
pressure than haplogroup MN females (P = 0.001 for both systolic and diastolic 24 h ABPM). 173 
Haplogroup MN males also had significantly higher blood pressure than their female 174 
counterparts (P = 0.003 for systolic 24 h ABPM; P < 0.0001 for diastolic 24 h ABPM). For 175 
blood glucose measurements (% of HbA1c) haplogroup L males had significantly higher 176 
values than both male and female groups from haplogroup MN (P < 0.0001), and only 177 
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slightly higher values than L haplogroup females (P = 0.03); haplogroup L females had 178 
significantly higher blood glucose levels than their haplogroup MN counterparts (P = 0.0004), 179 
(Fig. 1). These differences have been previously reported in the current cohort (Lammertyn et 180 
al., 2011; Hamer et al., 2015), and correlates well with similar discrepancies between 181 
population groups reported in other studies (reviewed by Mensah, 2013). Consequently, data 182 
were divided into four groups based on gender and mtDNA background and analysed 183 
separately for subsequent analysis. These groups were as follows: haplogroup L males (n = 184 
100); haplogroup L females (n = 94); haplogroup MN males (n = 75); and haplogroup MN 185 
females (n = 94).  186 
2.1 Functional network analysis 187 
We performed network analyses on our data, using only variants with MutPred scores above 188 
0.5, as well as rRNA and tRNA variants. Separate and simplified networks, shown in Fig. 2, 189 
were calculated for macro-haplogroups L and MN. Several occurrences of homoplasies were 190 
found in both macro-haplogroups (indicated in italics). This is not uncommon within the 191 
central regions of networks (Hernstadt et al., 2002). Activating the “frequency > 1” criterion, 192 
which then excludes all unique taxa, contributed greatly to simplifying the networks, but also 193 
resulted in the only participant from haplogroup L4 being excluded from Fig. 2A. The 194 
included nodes formed into clusters that correlated very well with the haplogroups that were 195 
assigned independently to each participant using the Haplogrep 2.0 program (Weissensteiner 196 
et al., 2016). It is interesting to note that the phenotype classifications do not group within 197 
specific parts of the network and seem well dispersed throughout the networks (Fig. 2).  198 
2.2 mtDNA variants  199 
We found very few heteroplasmies over 10% and therefor did not consider the possible 200 
contribution of these sites to the phenotypes investigated here. We also found no clinically 201 
proven mutations at appreciable heteroplasmies among any of our participants. In our current 202 
dataset, we found 17 changes not present in GenBank sequences. Of those, twelve changes 203 
were transitions and five changes were transversions. Four of these changes have however 204 
been previously reported, according to the MITOMAP database. The properties of these 205 
changes are listed in Table 2. 206 
To capture any differences in the population frequency of rare population alleles, we 207 
compared the number of rare (<0.1%) and common (>1%) non-synonymous population 208 
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alleles unique to each group as defined by haplogroup background (L or MN), gender and 209 
phenotype (in this analysis, a two-group classification for blood glucose levels were used 210 
instead of three groups, i.e., optimal or pre-diabetic glucose levels, using a cut-off of HbA1c 211 
= 5.7%). Although rare population allele counts were higher in both male and female 212 
haplogroup L hypertensives groups, as well as in the haplogroup L pre-diabetic group, these 213 
differences did not prove to be statistically significant. Possibly, the amount of rare 214 
population alleles identified in these groups is influenced by the under-representation of 215 
African sequences in the Genbank database, or the disproportionate number of haplogroup L 216 
participants that are classified as hypertensive (about 80%). As can be seen in Table 3, no 217 
statistically significant differences were found between any of the other groups when looking 218 
at either hypertension or hyperglycaemia.  219 
2.3 Mutational load calculations and adjustments using MutPred pathogenicity scores 220 
Next, MutPred adjusted loads, which serve as an estimate of the likely impact of a person’s 221 
non-synonymous mtDNA substitutions on the functioning of their mtDNA encoded proteins, 222 
were calculated as described in the Introduction. Since i) the possible pathogenicity of 223 
variants with a MutPred score greater than 0.5 can be considered an “actionable hypothesis” 224 
(Li et al., 2009), and ii) these higher scoring variants are thought to be rarer and less likely to 225 
be common population variants (Pereira et al., 2011), we applied specific MutPred score 226 
criteria while carrying out statistical analyses. Table S1 shows the sum of MutPred scores 227 
(MutPred mutational load), the number of MutPred scored variants, and the calculated 228 
MutPred adjusted load for each participant, using these different criteria. Table 4 summarises 229 
the data by giving the means and standard deviations for the above mentioned genetic 230 
parameters, when using either all MutPred scored variants, or only those with MutPred scores 231 
above the 0.5 threshold. The impact of the reference sequence location is greatly reduced 232 
when only variants with MutPred scores greater than 0.5 are considered. As shown in Fig. 3, 233 
doing this resulted in a 37% change in calculated MutPred adjusted loads in haplogroup L 234 
groups, but only a 13% change in haplogroup MN groups, underlining the utility of applying 235 
this type of correction in studies using diverse populations. As previously mentioned, variants 236 
with low MutPred scores are likely to be close to neutral; we do not expect these variants to 237 
impact on phenotype. This is supported by the lack of purification selection against these 238 
variants (Cavadas et al., 2015). Our own data also reflected this, as haplogroup L participants 239 
had an average of 10.2 variants with MutPred scores below 0.5, while haplogroup MN 240 
participants only had an average of four low scoring variants. This ratio is greatly reduced 241 
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when moving to the other side of the MutPred scale: haplogroup L participants had an 242 
average of 1.6 variants with MutPred scores above 0.5, while Haplogroup MN participants 243 
had an average of 1.1 variants with scores above this threshold. Excluding these variants 244 
(MutPred scores less than 0.5) from further statistical analyses that followed then also 245 
allowed us to minimise their impact on our genetic parameter (MutPred adjusted load). The 246 
large standard deviations present in Fig. 3, when only variants with MutPred scores above 0.5 247 
are included, can be attributed to the fact that 37% of participants (45 from haplogroup L and 248 
89 from haplogroup MN) do not have any variants above this threshold.  249 
2.4 Correlations between MutPred adjusted loads and measurements of blood pressure and 250 
blood glucose levels   251 
To determine if there is any relationship between MutPred adjusted loads and measurements 252 
of blood pressure (Table 5) or blood glucose (Table 6), Pearson’s correlation analyses were 253 
carried out for each of the four gender/mtDNA background groups. From Table 5, it can be 254 
seen that several MutPred adjusted loads were significantly correlated with blood pressure 255 
measurements. However, none of these significant associations remained after correcting for 256 
multiple comparisons. From Table 6, it can be seen that none of the MutPred adjusted loads, 257 
for either the entire mtDNA molecule, or those of individual electron transport chain (ETC) 258 
complexes, correlated significantly with blood glucose measurements.  259 
2.5 Comparison of MutPred scores between different classifications of blood pressure and 260 
blood glucose levels 261 
Next, we classified participants into different groups within the two CVD phenotypes that 262 
were investigated (hypertension and hyperglycaemia) as described in Materials and Methods 263 
(Table S1). To investigate the role of mtDNA variants in hypertension, we compared the 264 
mean values for genetic parameters of normotensive and hypertensive participants using 265 
independent t-tests. From Table 7, it is apparent that the total MutPred adjusted load differed 266 
significantly between normotensives and hypertensives within haplogroup L females, as well 267 
as haplogroup MN males. Similar to the above associations, after correction for multiple 268 
comparisons, significance was lost. We then compared the mean values for genetic 269 
parameters of participants with optimal blood glucose levels, those classified as pre-diabetic 270 
and those classified as diabetic within the different gender/mtDNA background groups, using 271 
one-way ANOVAS. None of these comparisons differed significantly (results not shown).  272 
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2.6 Comparison of high MutPred scoring variant frequency between different classifications 273 
of blood pressure and blood glucose levels  274 
To see if having one or more variants with very high MutPred pathogenicity scores can 275 
increase the risk of disease, we determined the frequency of these high scoring variants 276 
within the different classifications in our CVD phenotypes. The number of participants with 277 
one or more variants with MutPred scores above 0.6, 0.7 or 0.8 within each gender/mtDNA 278 
background group are listed in Table 8 (hypertension classifications) and Table 9 279 
(hyperglycaemia classifications). Also, in Fig. 4, the average number of variants per person 280 
belonging to a specific macro-haplogroup is represented. It can be seen that haplogroup L 281 
participants are no more likely than haplogroup MN participants to have one or more variants 282 
with a MutPred score above 0.6; haplogroup MN participants are slightly more likely to have 283 
at least one variant with a MutPred score above 0.7. For variants with MutPred scores above 284 
0.8, the average number of instances is higher in haplogroup L participants compared to 285 
haplogroup MN participants (0.03 vs. 0.005), but these refer to a very low number of counts. 286 
This data correlate well with previous reports by Pereira et al. (2011) and Cavadas et al. 287 
(2015), who demonstrated that high MutPred scoring variants are more numerous in more 288 
recent branches (here haplogroup MN) of the phylogenetic tree, than branches deeper within 289 
the phylogenetic tree (here haplogroup L), due to purification selection. However, we found 290 
no significant differences in the number of participants carrying high MutPred scoring 291 
variants when comparing normotensives with hypertensives in any of the groups. We also 292 
found no significant differences between the three hyperglycaemia classifications within any 293 
of the groups. 294 
 295 
3. Discussion 296 
From the landmark Framingham Heart Studies (Mahmood et al., 2014), several risk factors 297 
have been identified as significant predictors of hypertension. In the SABPA cohort also, 298 
these factors, which included gender and population group, significantly predicted blood 299 
pressure (Hamer et al., 2015; Malan et al., 2015). Disparities in CVD onset and development 300 
between different population groups are often linked to gross socio-economic inequality 301 
(Kaufman et al., 2015). However, it is important to note that even though participants were 302 
matched on several factors, including socio-economic status, this disparity is still present in 303 
the SABPA cohort. In this study also, we showed that both gender and background 304 
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contributed to significant differences in measurements of blood pressure and blood glucose. 305 
Consequently, the cohort was divided into four gender/mtDNA background groups and 306 
analysed separately as has been done in other studies using the SABPA participants. 307 
Assuming that rare non-synonymous population alleles (present in <0.1% of GenBank 308 
sequences) are more likely to be deleterious than common population alleles (present in >1% 309 
of GenBank sequences), one would expect rare population alleles to be present more 310 
frequently in the affected members of the cohort if mildly deleterious mtDNA variants were 311 
affecting susceptibility to disease. That was however not the case in our cohort, as no 312 
significant differences in the numbers of these population alleles were identified when the 313 
groups were compared. This is a less sophisticated analysis however, as the likelihood of 314 
pathogenicity of each allele is assumed, but not qualified by the use of more robust criteria. 315 
Using the MutPred program to qualify the pathogenicity of variants enabled us to carry out 316 
more sophisticated analyses. The usefulness of the MutPred scoring system to predict 317 
pathogenicity has been thoroughly demonstrated by Pereira et al. (2011) and Cavadas et al. 318 
(2015). 319 
Genetic parameters such as the MutPred mutational load per participant, the number of 320 
MutPred scored variants per participant, and the MutPred adjusted load per participant, were 321 
calculated using specified variant inclusion criteria. Because of the position of the revised 322 
Cambridge Reference Sequence (rCRS) in the phylogeny, African lineages are expected to 323 
have more variants than European lineages which lie closer on the phylogeny to the reference. 324 
Importantly, many of these variants have MutPred scores below 0.5, are common population 325 
polymorphisms, and thus have a low likelihood of being mildly deleterious. The exclusion of 326 
variants with MutPred scores below 0.5 reduced the differences in the mean number of 327 
variants between haplogroup L and MN groups. Interestingly, it also increased the mean 328 
MutPred adjusted loads in haplogroup L groups, while it decreased this mean in haplogroup 329 
MN groups (Table 4). However, some common haplogroup defining variants do have 330 
MutPred scores above 0.5, and are still included (Table S2). It is for this reason that a second 331 
step of correction is needed, i.e., adjusting mutational load scores according to sequence 332 
position within the phylogeny. By excluding these low-impact variants from analyses, and 333 
then calculating MutPred adjusted loads, any bias that is potentially introduced by 334 
phylogenetic distance, when utilizing mutational load methods, is largely corrected.  335 
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We investigated the role of mtDNA variants in the presentation (or severity) of two major 336 
CVD phenotypes (hypertension and hyperglycaemia). MutPred adjusted loads for variants 337 
with MutPred pathogenicity scores above 0.5 were used in correlation tests. Although some 338 
significant differences were found when comparing MutPred adjusted loads between 339 
hypertensives and normotensives, these significances were not robust enough to withstand 340 
corrections for multiple testing. No significant differences between any groups were found 341 
within the hyperglycaemia classifications.  342 
Although haplogroup L participants were more likely to have at least one high MutPred 343 
scoring variant above 0.5 than haplogroup MN participants, they were no more likely to have 344 
very high MutPred scoring variants (above 0.7). We found no significant relationship 345 
between the prevalence of potentially deleterious variants and any phenotypical classification. 346 
Thus, from our data, we could not identify a relationship between MutPred adjusted loads or 347 
high MutPred scoring variants and the presentation of our investigated phenotypes. We 348 
however did not investigate the role of these genetic parameters in the outcome of disease. It 349 
is also important to note that this study was not sufficiently powered to detect differences in 350 
individual ETC complexes, which would provide a much more refined outcome. We did 351 
however present a new and updated method for attempting to associate mtDNA variation 352 
with a complex trait. 353 
The current study is one of very few mtDNA genetic studies conducted in a cohort that 354 
includes African participants with extensively phenotyped CVD. The global burden of CVDs 355 
and the rising burden thereof in Africa make this collection of phenotypes especially 356 
important to investigate. More rare non-synonymous population alleles (present in <0.1% of 357 
GenBank sequences) were identified in haplogroup L participants than haplogroup MN 358 
participants, possibly influenced by the low presence of African sequences in the GenBank 359 
database. This underscores again the need to sequence more mtDNA from African 360 
populations, and especially from under-represented Southern African population groups. 361 
 Despite our data not indicating a statistically significant link between mtDNA variation and 362 
the two phenotypes investigated here, we are of the opinion that the method proposed here 363 
delivered well-powered results for the specific questions we posed, especially considering the 364 
modest size of the cohort. With the validity of the MutPred system being well established, we 365 
suggest the Mutational adjusted load method proposed here could be useful in similar 366 
investigations on other phenotypes and diseases. These investigations should indeed be 367 
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plentiful in the near future, with many associations between mtDNA variation and common 368 
complex disease being proposed.  369 
 370 
4. Materials and methods 371 
4.1 Cohort recruitment and sample collection 372 
We included participants of the SABPA cohort in this study. Details on participant 373 
recruitment, and sample and data collection have been published elsewhere (Hamer et al., 374 
2015; Malan et al., 2015). Inclusion criteria for the SABPA study were urban Black and 375 
Caucasian male and female teachers from South Africa (n = 409), with similar socio-376 
economic status, aged 20‒65 years, from the North-West Province (Malan et al., 2015). 377 
Participants were enrolled in the project in 2008‒2009, having their first follow up in 378 
2011‒2012. During recruitment and before consent, study participants were informed about 379 
the objectives and procedures of the study, including investigations of genes involved in 380 
CVD. The study complied with criteria on human research set by the Helsinki declaration 381 
(2004) and was approved by the Ethics Committee of the North-West University (NWU 382 
00036-07-S6). 383 
4.2 Sequencing and data management 384 
The complete mtDNA genome of each participant was sequenced at an average base 385 
coverage of about 1800× from two overlapping long range PCR products as previously 386 
described (van der Walt et al., 2012), using the Ion PGM and 200-bp templating and 387 
sequencing chemistry. This method was validated using two additional sequence chemistries 388 
(Illumina and pyrosequencing, QIAGEN, USA). Base calling and alignment were 389 
automatically performed by the Ion Torrent Suite 4.4 software. Variants were identified by 390 
the VariantCaller plug-in (version 5.0) using the rCRS (Andrews et al., 1999). A list of 391 
variants for each participant can be found in the supplementary file “JGG Supplementary 392 
variants SABPA”. Only consensus variants were used in this study. We did not investigate 393 
the effect of heteroplasmy here. Haplogroups were assigned using the online Haplogrep 2.0 394 
tool (haplogrep.uibk.ac.at). MutPred scores were assigned to all non-synonymous variants 395 
(mutpred.mutdb.org/about.html). MutPred adjusted loads were calculated by obtaining the 396 
average of N, where N is the set of MutPred score values for variants within a specific target 397 
region, i.e., a single gene, a set of genes within an enzyme complex or the entire mtDNA 398 
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genome.  A functional maximum parsimony (MP) network analysis was performed with the 399 
NETWORK (version 5) and NETWORK Publisher (version 2.0.0.1) software packages 400 
(http://www.fluxus-engineering.com/sharenet.htm), by using only mtDNA variants with 401 
MutPred pathogenicity scores above 0.5, rRNA variants and tRNA variants. The processing 402 
strategy to produce the networks, were aimed at reducing complexity (introduced by the large 403 
amount of sequences). Transversions, being chemically less likely to occur, were weighted 404 
three times more than transitions. Reduced median (RM) (Bandelt et al., 1995) processing 405 
split loci on the basis of genetic distance (reduction threshold r was 3 and 2 for macro-406 
haplogroup L and MN networks respectively). This step was followed by median joining (MJ) 407 
(Bandelt et al., 1999) to calculate all possible shortest trees (ε was set to 30 and 0 for macro-408 
haplogroup L and MN networks respectively) and produce a network. The “frequency > 1” 409 
criterion was activated to ignore unique sequences/taxa and reduce complexity. Finally, an 410 
MP clean-up step (Polzin and Daneschmand, 2003) was performed to remove unnecessary 411 
median vectors and links.  412 
All figures were produced using Excel (Microsoft Office 365) or NETWORK Publisher 413 
(version 2.0.0.1) and were finalised in PowerPoint (Microsoft Office 365) and Adobe 414 
Photoshop Elements (Version 10.0).   415 
4.3 Phenotyping  416 
Normotensive and hypertensive classifications are based on 24 h ABPM measurements. A 417 
hypertensive classification was assigned to males with 24 h systolic ABPM ≥ 130 mmHg 418 
and/or 24 h diastolic ABPM ≥ 80 mmHg, and females with 24 h systolic ABPM ≥ 125 419 
mmHg and/or 24 h diastolic ABPM ≥ 75 mmHg (Hermida et al., 2013; Mancia et al., 2013). 420 
Glycated haemoglobin (HbA1c) expressed as a percentage, which is measured to calculate 421 
the three month average plasma glucose concentration measurements, were used to classify 422 
participants as having either optimal blood glucose levels (HbA1c below 5.7%), falling 423 
within pre-diabetic ranges (HbA1c from 5.7% to 6.4%) or diabetic ranges (HbA1c above 424 
6.4%) (American Diabetes Accociation, 2010). For a two-group classification (optimal or 425 
pre-diabetic glucose levels), a cut-off value of HbA1c = 5.7% was used. 426 
4.4 Statistical analysis 427 
All statistical analyses were carried out using IBM SPSS Statistics (version 23) or Prism 428 
GraphPad Prism software (version 6.05). A one-way analysis of variance (ANOVA) followed 429 
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by a post-hoc Tuckey test, was carried out to assess the relationships between gender and 430 
mtDNA background and two CVD clinical measurements (blood pressure and blood glucose 431 
levels).  432 
The population frequency of rare population alleles, defined as having a frequency (Genbank 433 
frequency) below 0.1% on the global databases of more than 30000 sequences (MITOMAP: 434 
A human mitochondrial genome database. http://www.mitomap.org), was compared between 435 
those with optimal and those with high blood pressure or high blood glucose levels using a 436 
Fisher’s exact test.  437 
To assess the number of participants in each phenotype classification who possess one or 438 
more variants with MutPred pathogenicity scores above 0.6, 0.7 or 0.8, we applied Fisher’s 439 
exact tests; a Bonferroni correction for multiple testing was applied to both sets of 440 
comparisons. 441 
Pearson’s correlation analyses were used to assess the correlation between MutPred adjusted 442 
loads, blood pressure and blood glucose levels in each of the four gender/mtDNA background 443 
groups, using a Bonferroni correction for multiple comparisons.   444 
Mean MutPred adjusted loads of normotensive and hypertensive participants in the four 445 
groups were compared using independent t-tests, with a Bonferroni correction for multiple 446 
comparison. For participants with optimal blood glucose levels, those within pre-diabetic 447 
ranges, and those within diabetic ranges, mean MutPred adjusted loads were compared using 448 
one-way ANOVA, with a Tukey post-hoc test. 449 
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Table 1. Phenotypical data on SABPA cohort  608 
Parameter Haplogroup L 
male 
Haplogroup L 
female 
Haplogroup MN  
male 
Haplogroup MN  
female 
Number of participants (n) 100 94 75 94 
Age (years) 43.2 ± 8.17 45.7 ± 7.86 45.4 ± 10.5 44.5 ± 10.7 
Body mass index 27.6 ± 5.77 32.9 ± 7.23 29.0 ± 5.33 26.2 ± 5.74 
HbA1c (%) 6.23 ± 1.23 5.90 ± 1.14 5.66 ± 0.49 5.36 ± 0.29 
24 h systolic ABPM (mmHg) 137.7 ± 16.0 128.6 ± 15.2 128.1 ± 10.6 120.7 ± 12.7 
25 h diastolic ABPM (mmHg) 87.9 ± 10.7 78.8 ± 8.50 79.7 ± 7.72 73.8 ± 7.89 
For each parameter, the group mean value is given ± standard deviation. Body mass index is a measure of body fat based on height and weight. 609 
HbA1c, glycated haemoglobin is measured to calculate the three month average plasma glucose concentration. 24 h ABPM, 24 hour ambulatory 610 
blood pressure monitoring.  611 
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Table 2. A list of novel variants found in the current cohort 612 
rCRS 
position 
rCRS 
NT 
Variant 
NT 
Mutation type Gene Mutation effect MITOMAP report Conservation 
(%) 
MutPred 
pathogenicity 
score 
8423 C T transition MT-ATP8 syn: L→L - 88.9 - 
7351 T C transition MT-COI non-syn: L→P - 48.9 0.432 
7291 C T transition MT-COI non-syn: T→M - 86.7 0.353 
14945 G A transition MT-CYB non-syn: A→T - 40.0 0.523 
15577 C T transition MT-CYB syn: A→A - 97.8 - 
15124 A G transition MT-CYB syn: T→T Single published 97.8 - 
14718 A G transition MT-TE tRNA - 2.2 - 
4842 A G transition MT-ND2 non-syn: T→A Single unpublished 35.6 0.386 
5106 A G transition MT-ND2 non-syn: T→A - 20.0 0.379 
4479 C T transition MT-ND2 syn: L→L - 46.7 - 
13552 G A transition MT-ND5 non-syn: A→T - 84.4 0.513 
13538 T C transition MT-ND5 non-syn: M→T - 20.0 0.341 
2603 C A transversion MT-RNR2 rRNA - 100.0 - 
6320 T G transversion MT-COI syn: P→P - 22.2 - 
5232 C A transversion MT-ND2 non-syn: P→T Single unpublished 100.0 0.780 
4906 C A transversion MT-ND2 non-syn: S→Y - 53.3 0.535 
12969 C G transversion MT-ND5 syn: T→T Single unpublished 8.9 - 
 613 
A list of variants found in this cohort, but not present on GenBank is given. The nucleotide (NT) change for each position is given, followed by 614 
descriptive information about the variant. Four variants have been reported according to MITOMAP records, three are from unpublished records. 615 
syn, synonymous change; non-syn, non-synonymous change. 616 
 617 
 618 
 619 
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Table 3. Number of non-synonymous variants unique to each group 620 
GenBank frequency (%) HT group NT group P-value PD-BG group O-BG group P-value 
Haplogroup L male        
<0.1  18 3 1 13 4 1 
>1  5 1  4 1  
Haplogroup L female        
<0.1  14 2 1 6 10 0.19 
>1  9 2  1 9  
Haplogroup MN male        
<0.1  1 4 0.28 2 2 0.52 
>1  6 4  2 9  
Haplogroup MN female        
<0.1  8 3 0.38 2 8 1 
>1   4 4   2 7   
The number of non-synonymous variants were calculated according to set criteria: very rare variants were those that are present in less van 0.1% 621 
of GenBank sequences; common variants are those that are present in more than 1% of GenBank sequences. Only non-synonymous variants that 622 
are unique for a specific group as defined by haplogroup, gender and disease classification were counted. P-values for a two-tailed Fisher’s exact 623 
test are given next to counts. HT, hypertensive; NT, normotensive; PD-BG, pre-diabetic blood glucose levels; O-BG, optimal blood glucose 624 
levels. 625 
  626 
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Table 4. Summary of mtDNA variants parameters. 627 
Group MutPred mut. load per par. 
 
 Number of var. per par. 
 
 MutPred adj. load per par. 
 
  
All var. 
included 
Var. with MutPred 
scores > 0.5 
 All var. 
included 
Var. with MutPred 
scores > 0.5 
 All var. 
included 
Var. with MutPred 
scores > 0.5 
Haplogroup L male  3.94 ± 1.50 0.85 ± 0.80  11.5 ± 3.6 1.4 ± 1.3  0.33 ± 0.04 0.44 ± 0.26 
Haplogroup L female 4.18 ± 1.58 1.02 ± 0.99  12.1 ± 3.6 1.7 ± 1.7  0.34 ± 0.04 0.48 ± 0.23 
Haplogroup MN male 2.04 ± 1.01 0.70 ± 0.72  5.3 ± 2.4 1.1 ± 1.2  0.39 ± 0.05 0.34 ± 0.31 
Haplogroup MN female 1.94 ± 0.98 0.64 ± 0.66  4.9 ± 2.5 1 ± 1.1  0.40 ± 0.04 0.35 ± 0.31 
 628 
The means ± standard deviation are given for specified genetic parameters per group. MutPred mutational load is the sum of MutPred scores for 629 
either all variants per participant, or only for variants with a MutPred score above 0.5. Number of variants refer to those variants with a MutPred 630 
score. The MutPred adjusted load is the MutPred mutational load per participant divided by the number of variants per participant. MutPred, a 631 
pathogenicity score assigned to a variant using the MutPred program (mutpred.mutdb.org/about.html); mut, mutational; var, variants; par, 632 
participant; adj, adjusted.  633 
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 634 
Table 5. Pearson’s correlation coefficients for genetic parameters compared to mean values of 24 h ABPM measurements 635 
Group 
 
24 h 
ABPM 
Total cohort (n = 363)  Haplogroup L males 
(n = 100) 
 Haplogroup L females 
(n = 94) 
 Haplogroup MN males 
(n = 75) 
 Haplogroup MN females 
(n = 94) 
MutPred  Pearson r  MutPred  Pearson r  MutPred  Pearson r  MutPred  Pearson r  MutPred  Pearson r 
Total 
mtDNA 
Systolic 0.41 ± 0.28 .096  0.43 ± 0.25 .234
*
  0.48 ± 0.23 ‒.063  0.33 ± 0.31 ‒.110  0.34 ± 0.30 .156 
Diastolic  .075   .233
*
   ‒.067   ‒.241
*
   .122 
CI Systolic 0.37 ± 0.28 .051  0.41 ± 0.26 .110  0.45 ± 0.24 ‒.062  0.30 ± 0.30 ‒.073  0.28 ± 0.30 .011 
 Diastolic  .040   .128   ‒.050   ‒.198   ‒.052 
CIII Systolic 0.09 ± 0.22 ‒.105*  0.05 ± 0.17 ‒.018  0.07 ± 0.19 ‒.177  0.10 ± 0.23 ‒.015  0.12 ± 0.25 .037 
 Diastolic  ‒.129*   ‒.007   ‒.113   ‒.217   .001 
CIV Systolic 0.05 ± 0.17 .117
*
  0.07 ± 0.19 .217
*
  0.06 ± 0.19 ‒.014  0.01 ± 0.09 ‒.082  0.03 ± 0.13 .271** 
 Diastolic  .116
*
   .154   ‒.009   ‒.253*   .358** 
CV Systolic 0.07 ± 0.20 .067  0.05 ± 0.18 .271
**
  0.04 ± 0.16 .234
*
  0.05 ± 0.19 ‒.205  0.07 ± 0.21 .161 
 Diastolic  .009   .182   .093   ‒.164   .099 
Pearson’s correlations were carried out to investigate the relationship between MutPred adjusted loads for mtDNA loci as indicated, and blood 636 
pressure measurements. Means ± standard deviations of MutPred adjusted loads are given with Pearson’s correlation coefficients (r) for systolic 637 
and diastolic 24 h ambulatory blood pressure monitoring (24 h ABPM) respectively. Correlations of significance (before correction for multiple 638 
testing) are indicated in bold and by * (significant at the 0.05 level) and ** (significant at the 0.01 level). CI, NADH:ubiquinone oxidoreductase; 639 
CIII, cytochrome c oxidoreductase; CIV, cytochrome c oxidase; CV, ATP synthase.  640 
   641 
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Table 6. Pearson’s correlation coefficients for genetic parameters compared to blood glucose measurements 642 
Group Total cohort 
(n = 363) 
 Haplogroup L male 
(n = 100) 
 Haplogroup L female 
(n = 94) 
 Haplogroup MN male 
(n = 75) 
 Haplogroup MN female 
(n = 94) 
  MutPred  Pearson r  MutPred  Pearson r  MutPred  Pearson r  MutPred  Pearson r  MutPred  Pearson r 
Total 
mtDNA 
0.41 ± 0.28  .039  0.43 ± 0.25 .062  0.48 ± 0.23 ‒.003  0.33 ± 0.31 ‒.076  0.34 ± 0.30 ‒.147 
CI  0.37 ± 0.28 .048  0.41 ± 0.26 .013  0.45 ± 0.24 .019  0.30 ± 0.30 ‒.045  0.28 ± 0.30 ‒.164 
CIII  0.09 ± 0.22 ‒.064  0.05 ± 0.17 ‒.002  0.07 ± 0.19 .035  0.10 ± 0.23 ‒.099  0.12 ± 0.25 .006 
CIV  0.05 ± 0.17 .035  0.07 ± 0.19 .115  0.06 ± 0.19 ‒.040  0.01 ± 0.09 ‒.078  0.03 ± 0.13 ‒.069 
CV  0.07 ± 0.20 ‒.005  0.05 ± 0.18 ‒.040  0.04 ± 0.16 .181  0.05 ± 0.19 ‒.041  0.07 ± 0.21 .088 
Pearson’s correlations were carried out to investigate the relationship between MutPred adjusted loads for mtDNA loci as indicated, and blood 643 
glucose (HbA1c%) measurements.  Means ± standard deviations of MutPred adjusted loads are given with Pearson’s correlation coefficients (r). 644 
CI, NADH:ubiquinone oxidoreductase; CIII, cytochrome c oxidoreductase; CIV, cytochrome c oxidase; CV, ATP synthase.  645 
  646 
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Table 7. Mean MutPred adjusted loads of normotensive participants compared to that of hypertensive participants 647 
Group Blood 
pressure 
status 
 Total cohort 
(NT = 115, HT = 248) 
 Haplogroup L male 
(NT = 22, HT = 78) 
 Haplogroup L female 
(NT = 18, HT = 76) 
 Haplogroup MN male 
(NT = 33, HT = 42) 
 Haplogroup MN female 
(NT = 42, HT = 52) 
 MutPred   t (df)  MutPred   t (df)  MutPred   t (df)  MutPred   t (df)  MutPred   t (df) 
Total 
mtDNA 
Normal  0.41 ± 0.29 ‒0.06 (384)  0.32 ± 0.30 1.97 (28)  0.59 ± 0.04  ‒4.67 (89)**  0.41 ± 0.30  ‒2.01 (73)*  0.33 ± 0.31 0.24 (92) 
Hyper  0.4 ± 0.27   0.47 ± 0.23   0.45 ± 0.24   0.27 ± 0.30   0.35 ± 0.30  
CI  Normal  0.36 ± 0.29 0.21 (384)  0.32 ± 0.30 1.62 (29)  0.56 ± 0.14  ‒2.84 (46)**  0.36 ± 0.30 ‒1.5 (‒73)  0.28 ± 0.30 0.03 (92) 
 Hyper  0.37 ± 0.28   0.43 ± 0.25   0.43 ± 0.26   0.26 ± 0.30   0.28 ± 0.30  
CIII  Normal  0.12 ± 0.25 ‒1.59 (209)  0.05 ± 0.18 0.10 (98)  0.13 ± 0.25 ‒1.15 (‒20)  0.14 ± 0.27 ‒1.2 (‒57)  0.11 ± 0.25 0.45 (92) 
 Hyper  0.08 ± 0.20   0.05 ± 0.17   0.05 ± 0.17   0.07 ± 0.20   0.13 ± 0.26  
CIV  Normal  0.05 ± 0.18 ‒0.27 (384)  0.06 ± 0.19 0.30 (98)  0.15 ± 0.29 ‒1.48 (‒19)  0.03 ± 0.14 ‒1.4 (‒32)  0.01 ± 0.09 1.15 (85) 
 Hyper  0.05 ± 0.16   0.07 ± 0.19   0.04 ± 0.15   0 ± 0   0.04 ± 0.16  
CV  Normal  0.07 ± 0.21 ‒0.30 (384)  0.02 ± 0.13 0.83 (98)  0 ± 0  2.75 (75)**  0.09 ± 0.24 ‒1 (‒45)  0.07 ± 0.21 ‒0.03 (92) 
  Hyper  0.06 ± 0.19    0.06 ± 0.19    0.05 ± 0.17    0.02 ± 0.13    0.07 ± 0.21   
Independent t-tests were carried out to compare means of MutPred adjusted loads for mtDNA loci as indicated, between normotensive (NT) and 648 
hypertensive (HT) participants. Means ± standard deviations of MutPred adjusted loads are given with the test statistic (t) and degrees of 649 
freedom (df). Differences of significance (before correction for multiple testing) are indicated in bold and by * (significant at the 0.05 level) and 650 
** (significant at the 0.01 level). CI, NADH:ubiquinone oxidoreductase; CIII, cytochrome c oxidoreductase; CIV, cytochrome c oxidase; CV, 651 
ATP synthase.  652 
  653 
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Table 8. Number of participants within each gender, mtDNA background and blood pressure phenotype group having one or more variants with 654 
a MutPred score above 0.6, 0.7 or 0.8. 655 
Number of 
variants  
 Number of haplogroup L 
male 
 Number of haplogroup L 
female 
 Number of haplogroup MN 
male 
 Number of haplogroup MN 
female 
 NT (n = 22) HT (n = 78)  NT (n = 18) HT (n = 76)  NT (n = 33) HT (n = 42)  NT (n = 42) HT (n = 52) 
MutPred 
score > 0.6 
 
 
  
 
    
 
    
 
 
  
1  8 32  11 36  4 5  8 9 
2  4 10  2 6  15 11  10 18 
3  0 5  2 4  2 1  2 0 
4  0 0  1 1  0 0  0 0 
   
 
             
 
  
MutPred 
score > 0.7 
 
 
  
 
    
 
    
 
 
  
1  2 6  2 3  7 3  4 5 
2  0 0  1 0  0 0  0 0 
   
 
             
 
  
MutPred 
score > 0.8 
 
 
  
 
    
 
    
 
 
  
1  1 2  0 1  1 0  0 0 
2  0 0  1 0  0 0  0 0 
The number of participants in a specified group (e.g., hypertensive haplogroup L males) that have one or more variants (as indicated in the left 656 
first column) with a MutPred pathogenicity score above 0.6, 0.7 or 0.8 is given. Normotensive (NT) and hypertensive (HT) classifications are 657 
based on 24 hour systolic and diastolic ambulatory blood pressure measurements (24 h ABPM).   658 
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Table 9. Number of participants within each gender, mtDNA background and blood glucose phenotype group having one or more variants with a 659 
MutPred score above 0.6, 0.7 or 0.8 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
 673 
The number of participants in a specified group (e.g., African males with optimal blood glucose levels) that have one or more variants with a 674 
MutPred pathogenicity score above 0.6, 0.7 or 0.8 is given. HbA1c measurements were used to classify participants as having either optimal 675 
blood glucose levels (O-BG, optimal blood glucose levels, HbA1c < 5.7%), being prediabetic (PD-BG, prediabetic blood glucose levels, HbA1c 676 
from 5.7% to 6.4%) or diabetic (D-BG, diabetic blood glucose levels, HbA1c > 6.4%). 677 
Number of 
variants 
Number of haplogroup L 
male 
 Number of haplogroup L 
female 
 
 Number of haplogroup MN 
male 
 Number of haplogroup MN 
female 
O-BG 
(n = 30) 
PD-BG 
(n = 51) 
D-BG  
(n =19) 
 O-BG  
(n = 45) 
PD-BG 
(n = 41) 
D-BG 
(n = 8) 
 O-BG  
(n = 45) 
PD-BG 
(n = 27) 
D-BG 
(n = 3) 
 O-BG  
(n = 77) 
PD-BG 
(n = 16) 
D-BG 
(n = 1) 
   
MutPred 
score > 0.6 
  
 
  
 
  
 
  
 
  
 
  
 
  
  
1 9 23 8  18 21 7  6 3 0  15 1 0 
2 3 9 2  5 3 0  14 11 1  24 4 0 
3 2 2 1  3 3 0  2 1 0  2 0 0 
4 0 0 0  1 1 0  0 0 0  0 0 0 
    
 
     
 
     
 
   
  
  
MutPred 
score > 0.7   
 
  
 
  
 
  
 
  
 
  
 
  
  
1 2 4 2  3 2 0  5 5 0  8 1 0 
2 0 0 0  0 1 0  0 0 0  0 0 0 
    
 
     
 
     
 
   
  
  
MutPred 
score > 0.8   
 
  
 
  
 
  
 
  
 
  
 
  
  
1 1 2 0  1 0 0  0 1 0  0 0 0 
2 0 0 0  0 1 0  0 0 0  0 0 0 
31 
 
List of figures 678 
Fig. 1. Comparison of differences in systolic and diastolic 24 hour ambulatory blood pressure 679 
monitoring measurements (ABPM), and glycated haemoglobin (HbA1c) as representation of 680 
blood glucose level, between gender and mtDNA background groups. ** P-value < 0.0001; * 681 
P-value < 0.001; ‡ P-value < 0.01; † P-value < 0.05 682 
Fig. 2. Networks of haplogroup L (A) and haplogroup MN (B) participants. Ellipses indicate 683 
clusters of branches forming sub-haplogroups. Red nodes indicate potential median vectors. 684 
Coloured pie-chart nodes indicate the proportion of individuals per phenotype classification, 685 
as well as the number of participants per node. mtDNA variants responsible for links are 686 
listed in boxes; homoplasic variants are shown in italics, while transversions are shown in 687 
bold and marked with an * 688 
Fig. 3. Representation of the effect on MutPred adjusted load when a correction is applied to 689 
address population stratification. 690 
Fig. 4. The average number of variants with MutPred scores above different thresholds, per 691 
person within a specific haplogroup (L or MN). 692 
 693 
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Table S1. Important phenotypical and genetic data for each participant 
 
Gender 24 h 
systolic / 
diastolic 
ABPM 
(mmHg) 
HbA1c (%) Blood pressure and 
blood glucose 
classifications 
Complete cohort  Variants with a 
MutPred pathogenicity 
score above 0.3 
 Variants with a 
MutPred pathogenicity 
score above 0.5 
 Variants with a 
MutPred pathogenicity 
score above 0.6 
Mut. 
load 
Num 
of 
var  
Adj 
load 
 Mut. 
load 
Num 
of 
var  
Adj 
load 
 Mut. 
load 
Num 
of 
var  
Adj 
load 
 Mut. 
load 
Num 
of 
var  
Adj 
load 
Haplogroup L participants 
Male 136 / 82 5.5 Hyper and optimal 4.97 13 0.38  4.24 9 0.47  1.92 3 0.64  1.92 3 0.64 
Male 148 / 83 5.7 Hyper and pre-diabetic 7.63 19 0.40  6.93 15 0.46  3.38 6 0.56  1.82 3 0.61 
Male 152 / 97 6.4 Hyper and pre-diabetic 4.65 14 0.33  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 124 / 74 5.7 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 145 / 89 6.1 Hyper and pre-diabetic 2.67 8 0.33  2.19 5 0.44  0.56 1 0.56  0.00 0 0.00 
Female 143 / 75 5.8 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 181 / 112 6.1 Hyper and pre-diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 136 / 82 5.3 Hyper and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 124 / 70 6.4 Hyper and pre-diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 121 / 78 6 Hyper and pre-diabetic 4.87 14 0.35  4.21 10 0.42  0.61 1 0.61  0.61 1 0.61 
Female 117 / 77 5 Hyper and optimal 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 145 / 93 6.1 Hyper and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 158 / 101 12.3 Hyper and diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 143 / 90 5.9 Hyper and pre-diabetic 3.21 10 0.32  2.29 5 0.46  1.12 2 0.56  0.61 1 0.61 
Male 147 / 97 5.6 Hyper and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 146 / 95 10.4 Hyper and diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 137 / 78 5 Hyper and optimal 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 157 / 105 6.2 Hyper and pre-diabetic 4.65 14 0.33  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 124 / 81 6.3 Hyper and pre-diabetic 4.89 14 0.35  4.23 10 0.42  1.12 2 0.56  0.61 1 0.61 
Male 144 / 91 6.5 Hyper and diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Table
Male 147 / 75 5.4 Hyper and optimal 5.12 13 0.39  4.40 9 0.49  2.07 3 0.69  2.07 3 0.69 
Male 138 / 90 5.5 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 131 / 86 8.8 Hyper and diabetic 8.38 20 0.42  7.68 16 0.48  4.00 7 0.57  2.44 4 0.61 
Male 142 / 100 5.8 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 113 / 71 5.3 Normal and optimal 5.54 14 0.40  5.06 11 0.46  1.87 3 0.62  1.87 3 0.62 
Male 154 / 103 6.8 Hyper and diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 121 / 79 5.6 Normal and optimal 7.11 18 0.40  6.39 14 0.46  2.97 5 0.59  1.91 3 0.64 
Female 151 / 78 5.7 Hyper and pre-diabetic 1.85 7 0.26  1.16 3 0.39  0.00 0 0.00  0.00 0 0.00 
Female 110 / 64 5 Normal and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 123 / 73 5.8 Hyper and pre-diabetic 5.58 16 0.35  4.61 11 0.42  0.61 1 0.61  0.61 1 0.61 
Female 123 / 74 7.3 Hyper and diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 136 / 85 6.9 Hyper and diabetic 8.41 20 0.42  7.70 16 0.48  4.28 7 0.61  3.21 5 0.64 
Female 137 / 75 5.7 Hyper and pre-diabetic 2.64 8 0.33  2.16 5 0.43  0.00 0 0.00  0.00 0 0.00 
Female 125 / 82 11.2 Hyper and diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 133 / 82 5.1 Hyper and optimal 7.68 19 0.40  6.96 15 0.46  3.54 6 0.59  2.47 4 0.62 
Female 124 / 79 5.7 Hyper and pre-diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 111 / 65 5.5 Normal and optimal 5.55 14 0.40  4.83 10 0.48  2.07 3 0.69  2.07 3 0.69 
Female 132 / 84 6.3 Hyper and pre-diabetic 4.94 13 0.38  4.21 9 0.47  1.46 2 0.73  1.46 2 0.73 
Male 136 / 83 6.3 Hyper and pre-diabetic 5.38 15 0.36  4.48 10 0.45  1.85 3 0.62  1.34 2 0.67 
Male 112 / 73 5.7 Normal and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 139 / 90 5.7 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 152 / 108 6.8 Hyper and diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 145 / 87 6.5 Hyper and diabetic 3.28 9 0.36  2.80 6 0.47  1.15 2 0.57  1.15 2 0.57 
Male 131 / 84 5.7 Hyper and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 154 / 95 8.7 Hyper and diabetic 7.68 19 0.40  6.96 15 0.46  3.54 6 0.59  2.47 4 0.62 
Female 132 / 86 5.1 Hyper and optimal 3.92 10 0.39  3.44 7 0.49  1.79 3 0.60  1.79 3 0.60 
Male 147 / 102 10.1 Hyper and diabetic 4.36 13 0.34  3.63 9 0.40  0.61 1 0.61  0.61 1 0.61 
Female 133 / 84 5.7 Hyper and pre-diabetic 6.41 15 0.43  5.69 11 0.52  2.91 4 0.73  2.91 4 0.73 
Male 151 / 94 6.6 Hyper and diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 150 / 82 6.8 Hyper and diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 114 / 67 5.6 Normal and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 154 / 100 7.5 Hyper and diabetic 4.15 12 0.35  3.42 8 0.43  0.61 1 0.61  0.61 1 0.61 
Male 130 / 84 5.5 Hyper and optimal 5.20 13 0.40  4.72 10 0.47  2.38 4 0.60  1.29 2 0.64 
Male 135 / 87 5.6 Hyper and optimal 5.35 15 0.36  4.67 11 0.42  1.29 2 0.65  1.29 2 0.65 
Male 157 / 91 6.3 Hyper and pre-diabetic 5.20 13 0.40  4.72 10 0.47  2.38 4 0.60  1.29 2 0.64 
Male 161 / 111 5.5 Hyper and optimal 5.08 14 0.36  4.42 10 0.44  1.31 2 0.66  1.31 2 0.66 
Male 138 / 87 6.4 Hyper and pre-diabetic 2.65 8 0.33  2.17 5 0.43  0.00 0 0.00  0.00 0 0.00 
Male 111 / 73 5.6 Normal and optimal 3.25 10 0.32  2.50 6 0.42  0.62 1 0.62  0.62 1 0.62 
Male 142 / 96 5.4 Hyper and optimal 4.60 14 0.33  3.44 8 0.43  1.12 2 0.56  0.62 1 0.62 
Female 126 / 83 5.7 Hyper and pre-diabetic 4.11 11 0.37  3.64 8 0.45  1.20 2 0.60  0.67 1 0.67 
Female 144 / 84 5.7 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 133 / 72 6.2 Hyper and pre-diabetic 1.55 6 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 107 / 62 7.6 Normal and diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 123 / 75 5.9 Normal and pre-diabetic 4.40 13 0.34  3.43 8 0.43  1.64 3 0.55  0.58 1 0.58 
Male 118 / 79 5.7 Normal and pre-diabetic 5.38 15 0.36  4.48 10 0.45  1.85 3 0.62  1.34 2 0.67 
Male 140 / 84 6.1 Hyper and pre-diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 137 / 78 6.2 Hyper and pre-diabetic 6.98 18 0.39  6.26 14 0.45  3.28 6 0.55  1.15 2 0.58 
Female 115 / 73 5.3 Normal and optimal 5.00 14 0.36  4.35 10 0.43  1.24 2 0.62  1.24 2 0.62 
Male 134 / 96 5.9 Hyper and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 129 / 83 5.7 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 119 / 79 5.4 Hyper and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 107 / 71 6.2 Normal and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 126 / 90 5.5 Hyper and optimal 7.26 18 0.40  6.56 14 0.47  3.38 6 0.56  1.82 3 0.61 
Male 122 / 75 6 Normal and pre-diabetic 5.00 15 0.33  4.11 10 0.41  1.14 2 0.57  0.63 1 0.63 
Male 135 / 86 5.9 Hyper and pre-diabetic 3.94 12 0.33  3.28 8 0.41  0.61 1 0.61  0.61 1 0.61 
Female 140 / 87 6 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 119 / 78 5.7 Hyper and pre-diabetic 3.23 9 0.36  2.75 6 0.46  1.21 2 0.61  1.21 2 0.61 
Female 116 / 73 5.6 Normal and optimal 2.60 8 0.33  2.13 5 0.43  0.00 0 0.00  0.00 0 0.00 
Male 132 / 82 5.8 Hyper and pre-diabetic 5.20 14 0.37  4.72 11 0.43  1.67 3 0.56  1.15 2 0.58 
Male 124 / 79 6.3 Normal and pre-diabetic 4.90 13 0.38  4.42 10 0.44  1.31 2 0.66  1.31 2 0.66 
Female 117 / 75 5.7 Hyper and pre-diabetic 1.55 6 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 121 / 73 5.4 Hyper and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 144 / 90 5.5 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 131 / 71 5.7 Hyper and pre-diabetic 2.11 7 0.30  1.64 4 0.41  0.00 0 0.00  0.00 0 0.00 
Female 120 / 70 6.3 Hyper and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 113 / 73 5.4 Normal and optimal 5.34 15 0.36  4.61 11 0.42  0.61 1 0.61  0.61 1 0.61 
Female 127 / 79 5.8 Hyper and pre-diabetic 4.39 14 0.31  3.24 8 0.41  0.51 1 0.51  0.00 0 0.00 
Female 130 / 81 5 Hyper and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 123 / 80 5.2 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 119 / 74 5.8 Normal and pre-diabetic 2.26 7 0.32  1.79 4 0.45  0.56 1 0.56  0.00 0 0.00 
Female 105 / 68 6.1 Normal and pre-diabetic 1.82 6 0.30  1.34 3 0.45  0.52 1 0.52  0.00 0 0.00 
Female 116 / 77 5.4 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 113 / 74 6.4 Normal and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 139 / 91 5.7 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 163 / 100 6 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 132 / 85 5.4 Hyper and optimal 1.13 4 0.28  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 162 / 96 6.3 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 148 / 94 9.5 Hyper and diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 128 / 88 6 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 135 / 94 6.3 Hyper and pre-diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 152 / 96 6.1 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 133 / 88 6.4 Hyper and pre-diabetic 4.52 14 0.32  3.36 8 0.42  1.04 2 0.52  0.00 0 0.00 
Male 118 / 78 5.1 Normal and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 130 / 82 6.4 Hyper and pre-diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 140 / 88 5.6 Hyper and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 148 / 92 6.2 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 125 / 85 7.4 Hyper and diabetic 4.90 13 0.38  4.42 10 0.44  1.31 2 0.66  1.31 2 0.66 
Female 133 / 83 5 Hyper and optimal 5.12 13 0.39  4.40 9 0.49  2.07 3 0.69  2.07 3 0.69 
Female 130 / 84 6.3 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 132 / 90 6.3 Hyper and pre-diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 132 / 85 5.3 Hyper and optimal 3.92 10 0.39  3.44 7 0.49  1.79 3 0.60  1.79 3 0.60 
Female 115 / 67 5.2 Normal and optimal 2.84 8 0.35  2.36 5 0.47  0.66 1 0.66  0.66 1 0.66 
Male 144 / 92 5.9 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 145 / 85 6.2 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 179 / 88 5.6 Hyper and optimal 2.97 10 0.30  2.05 5 0.41  0.51 1 0.51  0.00 0 0.00 
Male 199 / 126 5.9 Hyper and pre-diabetic 3.94 12 0.33  3.28 8 0.41  0.61 1 0.61  0.61 1 0.61 
Female 130 / 77 5.5 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 129 / 78 5.3 Hyper and optimal 1.55 6 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 127 / 81 5.9 Hyper and pre-diabetic 4.32 13 0.33  3.17 7 0.45  1.29 2 0.64  0.78 1 0.78 
Female 115 / 64 6 Normal and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 129 / 82 6.1 Hyper and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 140 / 84 5.5 Hyper and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 131 / 82 5.7 Hyper and pre-diabetic 6.83 17 0.40  6.13 13 0.47  3.38 6 0.56  1.82 3 0.61 
Female 117 / 78 5.3 Hyper and optimal 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 110 / 72 5.3 Normal and optimal 4.03 10 0.40  3.72 8 0.46  1.84 3 0.61  1.34 2 0.67 
Female 111 / 72 5.2 Normal and optimal 2.65 8 0.33  2.17 5 0.43  0.00 0 0.00  0.00 0 0.00 
Female 111 / 73 5.5 Normal and optimal 5.75 15 0.38  5.28 12 0.44  1.79 3 0.60  1.29 2 0.64 
Female 130 / 84 6.2 Hyper and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 122 / 72 6.1 Normal and pre-diabetic 3.23 9 0.36  2.75 6 0.46  1.21 2 0.61  1.21 2 0.61 
Male 172 / 111 5.4 Hyper and optimal 3.23 9 0.36  2.75 6 0.46  1.21 2 0.61  1.21 2 0.61 
Male 112 / 72 5.8 Normal and pre-diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 168 / 90 5.2 Hyper and optimal 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 139 / 92 5.2 Hyper and optimal 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 145 / 91 5.1 Hyper and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 116 / 78 5.3 Hyper and optimal 4.71 13 0.36  4.24 10 0.42  1.12 2 0.56  0.61 1 0.61 
Female 115 / 75   Hyper and  7.11 18 0.40  6.39 14 0.46  2.97 5 0.59  1.91 3 0.64 
Male 114 / 77 5.7 Normal and pre-diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 154 / 94 6.6 Hyper and diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 140 / 94 5.4 Hyper and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 117 / 72 5.4 Normal and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 148 / 93 7.4 Hyper and diabetic 6.04 17 0.36  4.98 11 0.45  1.78 3 0.59  1.26 2 0.63 
Female 130 / 82 6.4 Hyper and pre-diabetic 4.85 14 0.35  3.97 9 0.44  1.64 3 0.55  0.61 1 0.61 
Female 130 / 85 5.6 Hyper and optimal 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 117 / 80 5.3 Hyper and optimal 6.79 16 0.42  6.48 14 0.46  2.86 5 0.57  1.82 3 0.61 
Female 129 / 86 5.5 Hyper and optimal 3.60 11 0.33  2.90 7 0.41  0.55 1 0.55  0.00 0 0.00 
Female 135 / 85 5.7 Hyper and pre-diabetic 3.73 10 0.37  3.25 7 0.46  1.71 3 0.57  1.21 2 0.61 
Female 145 / 88 6.1 Hyper and pre-diabetic 7.11 18 0.40  6.39 14 0.46  2.97 5 0.59  1.91 3 0.64 
Female 129 / 70 5.7 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 137 / 76 5.5 Hyper and optimal 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 141 / 94 5.4 Hyper and optimal 4.81 13 0.37  4.34 10 0.43  1.23 2 0.61  1.23 2 0.61 
Male 140 / 89 5.9 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 117 / 77 6.2 Normal and pre-diabetic 1.98 6 0.33  1.50 3 0.50  0.68 1 0.68  0.68 1 0.68 
Male 128 / 76 6.1 Normal and pre-diabetic 3.97 12 0.33  3.25 8 0.41  0.61 1 0.61  0.61 1 0.61 
Male 122 / 82 5.1 Hyper and optimal 3.21 10 0.32  2.29 5 0.46  1.12 2 0.56  0.61 1 0.61 
Male 146 / 100 6.1 Hyper and pre-diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 124 / 80 5.2 Hyper and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 135 / 87 5.5 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 123 / 79 5.9 Normal and pre-diabetic 5.38 15 0.36  4.48 10 0.45  1.85 3 0.62  1.34 2 0.67 
Male 158 / 101 9.6 Hyper and diabetic 3.92 10 0.39  3.44 7 0.49  1.79 3 0.60  1.79 3 0.60 
Male 125 / 82 9.4 Hyper and diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 114 / 68 5.6 Normal and optimal 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 124 / 79 6 Normal and pre-diabetic 5.86 16 0.37  4.97 11 0.45  2.33 4 0.58  1.83 3 0.61 
Female 160 / 98 5.7 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 181 / 112 9.6 Hyper and diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 121 / 66 5.3 Hyper and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 111 / 65 6.2 Normal and pre-diabetic 5.16 14 0.37  4.68 11 0.43  1.11 2 0.56  0.61 1 0.61 
Female 113 / 77 5.3 Hyper and optimal 4.40 13 0.34  3.43 8 0.43  1.64 3 0.55  0.58 1 0.58 
Male 161 / 97 5.9 Hyper and pre-diabetic 4.21 12 0.35  3.48 8 0.44  1.16 2 0.58  0.61 1 0.61 
Female 122 / 77 5.9 Hyper and pre-diabetic 4.93 14 0.35  4.20 10 0.42  0.61 1 0.61  0.61 1 0.61 
Male 124 / 79 6 Normal and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Female 104 / 63 5.2 Normal and optimal 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 160 / 84 12.8 Hyper and diabetic 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 131 / 82 6.5 Hyper and diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 112 / 74 5.6 Normal and optimal 4.66 13 0.36  4.18 10 0.42  0.61 1 0.61  0.61 1 0.61 
Male 161 / 108 5.8 Hyper and pre-diabetic 5.23 14 0.37  4.24 9 0.47  1.92 3 0.64  1.92 3 0.64 
Female 126 / 82 5 Hyper and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 120 / 74 5.2 Hyper and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 158 / 94 5.8 Hyper and pre-diabetic 4.42 13 0.34  3.69 9 0.41  0.61 1 0.61  0.61 1 0.61 
Male 138 / 93 6.7 Hyper and diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 129 / 82 5.6 Hyper and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 124 / 83 6.1 Hyper and pre-diabetic 5.34 15 0.36  4.61 11 0.42  0.61 1 0.61  0.61 1 0.61 
Female 126 / 81 6.2 Hyper and pre-diabetic 3.46 10 0.35  2.89 7 0.41  0.51 1 0.51  0.00 0 0.00 
Female 122 / 68 5.5 Hyper and optimal 7.26 18 0.40  6.56 14 0.47  3.38 6 0.56  1.82 3 0.61 
Female 131 / 86 4.8 Hyper and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Female 145 / 78 5.8 Hyper and pre-diabetic 5.34 15 0.36  4.61 11 0.42  0.61 1 0.61  0.61 1 0.61 
Male 131 / 87 5.7 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Male 111 / 72 5.5 Normal and optimal 4.93 14 0.35  4.20 10 0.42  0.61 1 0.61  0.61 1 0.61 
Male 122 / 74 5.2 Normal and optimal 4.66 14 0.33  3.77 9 0.42  1.14 2 0.57  0.63 1 0.63 
Male 132 / 78 9.2 Hyper and diabetic 4.38 13 0.34  3.72 9 0.41  0.61 1 0.61  0.61 1 0.61 
Female 121 / 74 5.5 Hyper and optimal 1.55 6 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 127 / 73 5.2 Hyper and optimal 4.93 14 0.35  4.20 10 0.42  0.61 1 0.61  0.61 1 0.61 
Male 153 / 90 5.6 Hyper and optimal 4.56 13 0.35  4.09 10 0.41  0.61 1 0.61  0.61 1 0.61 
Male 135 / 98 5.6 Hyper and optimal 5.54 14 0.40  5.06 11 0.46  1.87 3 0.62  1.87 3 0.62 
Male 163 / 97 6.3 Hyper and pre-diabetic 2.18 7 0.31  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Haplogroup MN participants 
Male 133 / 93 5.5 Hyper and optimal 1.35 5 0.27  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 123 / 68 5.6 Hyper and optimal 3.43 8 0.43  3.02 6 0.50  1.81 3 0.60  1.26 2 0.63 
Female 190 / 119 5.2 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 128 / 85 5.6 Hyper and optimal 2.09 5 0.42  1.93 4 0.48  1.11 2 0.55  0.00 0 0.00 
Female 131 / 72 5.3 Hyper and optimal 4.11 11 0.37  3.33 7 0.48  1.71 3 0.57  1.20 2 0.60 
Female 123 / 83 5.7 Hyper and pre-diabetic 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 120 / 70 5 Hyper and optimal 2.06 6 0.34  1.65 4 0.41  0.00 0 0.00  0.00 0 0.00 
Female 111 / 67 5.5 Normal and optimal 3.13 8 0.39  2.86 6 0.48  1.22 2 0.61  1.22 2 0.61 
Female 110 / 70 5.4 Normal and optimal 3.88 9 0.43  3.61 7 0.52  1.97 3 0.66  1.97 3 0.66 
Male 124 / 82 6.1 Hyper and pre-diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 132 / 83 5.6 Hyper and optimal 1.13 3 0.38  1.13 3 0.38  0.00 0 0.00  0.00 0 0.00 
Male 126 / 81 5.7 Hyper and pre-diabetic 2.53 7 0.36  2.11 5 0.42  0.00 0 0.00  0.00 0 0.00 
Female 113 / 69 6.3 Normal and pre-diabetic 4.11 11 0.37  3.33 7 0.48  1.71 3 0.57  1.20 2 0.60 
Female 113 / 70 5.7 Normal and pre-diabetic 2.26 6 0.38  1.92 4 0.48  0.61 1 0.61  0.61 1 0.61 
Female 111 / 69 5.3 Normal and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 118 / 72 5.4 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 112 / 69 5.7 Normal and pre-diabetic 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 113 / 72 5.6 Normal and optimal 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 116 / 76 5.3 Hyper and optimal 4.94 12 0.41  4.31 9 0.48  1.27 2 0.64  0.77 1 0.77 
Female 117 / 71 5.1 Normal and optimal 2.78 8 0.35  2.16 5 0.43  0.51 1 0.51  0.00 0 0.00 
Female 120 / 73 5.1 Hyper and optimal 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 130 / 79 5.4 Hyper and optimal 1.44 4 0.36  1.17 3 0.39  0.00 0 0.00  0.00 0 0.00 
Female 120 / 74 5.5 Hyper and optimal 1.14 4 0.28  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 133 / 81 5.3 Hyper and optimal 3.25 9 0.36  2.82 6 0.47  1.22 2 0.61  1.22 2 0.61 
Male 135 / 89 5.2 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 129 / 82 5.3 Hyper and optimal 2.84 7 0.41  2.51 5 0.50  1.19 2 0.60  1.19 2 0.60 
Male 158 / 94 6.3 Hyper and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 133 / 79 7.8 Hyper and diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 120 / 79 5.2 Hyper and optimal 2.57 7 0.37  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Female 110 / 61 5.2 Normal and optimal 1.50 3 0.50  1.50 3 0.50  0.68 1 0.68  0.68 1 0.68 
Male 128 / 69 5.1 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 168 / 84 5.7 Hyper and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 126 / 82 5.7 Hyper and pre-diabetic 2.82 7 0.40  2.56 5 0.51  1.74 3 0.58  1.24 2 0.62 
Female 124 / 70 5.3 Hyper and optimal 1.22 4 0.30  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 124 / 79 5.2 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 117 / 71 5.4 Normal and optimal 1.85 6 0.31  1.22 3 0.41  0.00 0 0.00  0.00 0 0.00 
Female 120 / 78 5.2 Hyper and optimal 2.80 7 0.40  2.09 4 0.52  1.27 2 0.64  1.27 2 0.64 
Female 133 / 80 5.6 Hyper and optimal 3.99 10 0.40  3.55 7 0.51  1.91 3 0.64  1.40 2 0.70 
Male 125 / 78 5.7 Normal and pre-diabetic 1.76 5 0.35  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Male 123 / 80 5.8 Hyper and pre-diabetic 2.96 9 0.33  2.24 5 0.45  1.09 2 0.55  0.57 1 0.57 
Female 129 / 81 5.4 Hyper and optimal 4.11 11 0.37  3.33 7 0.48  1.71 3 0.57  1.20 2 0.60 
Female 112 / 72 5.1 Normal and optimal 5.59 15 0.37  4.87 11 0.44  1.29 2 0.64  1.29 2 0.64 
Female 124 / 77 5.6 Hyper and optimal 2.57 7 0.37  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Female 125 / 83 5.1 Hyper and optimal 7.12 17 0.42  6.10 12 0.51  2.86 4 0.72  2.86 4 0.72 
Female 126 / 74 5.4 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 109 / 70 5 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 122 / 74 5 Hyper and optimal 2.88 8 0.36  2.45 5 0.49  1.22 2 0.61  1.22 2 0.61 
Female 122 / 79 5.6 Hyper and optimal 4.11 11 0.37  3.33 7 0.48  1.71 3 0.57  1.20 2 0.60 
Male 118 / 74 5.2 Normal and optimal 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Male 114 / 66 5.1 Normal and optimal 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 124 / 72 5.8 Normal and pre-diabetic 3.88 9 0.43  3.61 7 0.52  1.97 3 0.66  1.97 3 0.66 
Male 150 / 91 5.6 Hyper and optimal 1.76 5 0.35  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Male 136 / 78 5.2 Hyper and optimal 6.40 15 0.43  5.63 11 0.51  2.86 4 0.72  2.86 4 0.72 
Female 123 / 74 6.3 Hyper and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 104 / 66 5.6 Normal and optimal 3.52 8 0.44  3.26 6 0.54  2.43 4 0.61  1.88 3 0.63 
Female 107 / 61 5.1 Normal and optimal 2.57 7 0.37  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Female 137 / 76 5.1 Hyper and optimal 1.36 3 0.45  1.36 3 0.45  0.54 1 0.54  0.00 0 0.00 
Male 124 / 81 5.3 Hyper and optimal 2.32 6 0.39  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Male 124 / 86 5 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 139 / 87 6.4 Hyper and pre-diabetic 1.76 5 0.35  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Female 110 / 66 5.4 Normal and optimal 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Female 102 / 61 5.1 Normal and optimal 1.71 4 0.43  1.71 4 0.43  0.00 0 0.00  0.00 0 0.00 
Female 106 / 70 5.8 Normal and pre-diabetic 2.26 6 0.38  1.92 4 0.48  0.61 1 0.61  0.61 1 0.61 
Female 122 / 70 5.5 Hyper and optimal 2.06 4 0.51  2.06 4 0.51  1.24 2 0.62  1.24 2 0.62 
Female 126 / 73 5.3 Hyper and optimal 2.32 6 0.39  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Male 140 / 82 5.2 Hyper and optimal 1.79 5 0.36  1.52 4 0.38  0.00 0 0.00  0.00 0 0.00 
Female 121 / 72 5.6 Hyper and optimal 1.80 4 0.45  1.80 4 0.45  0.62 1 0.62  0.62 1 0.62 
Female 111 / 66 4.8 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 135 / 80 5.3 Hyper and optimal 2.62 6 0.44  2.46 5 0.49  1.29 2 0.65  1.29 2 0.65 
Female 115 / 77 5 Hyper and optimal 1.59 4 0.40  1.59 4 0.40  0.00 0 0.00  0.00 0 0.00 
Female 119 / 71 5.3 Normal and optimal 2.93 7 0.42  2.59 5 0.52  1.28 2 0.64  1.28 2 0.64 
Male 127 / 71 5.6 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 147 / 93 6.1 Hyper and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 113 / 75 5.5 Normal and optimal 3.99 10 0.40  3.55 7 0.51  1.91 3 0.64  1.40 2 0.70 
Male 122 / 82 5.5 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 126 / 67 5.7 Normal and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 115 / 63 5.2 Normal and optimal 1.68 3 0.56  1.68 3 0.56  0.86 1 0.86  0.86 1 0.86 
Female 112 / 59 5.2 Normal and optimal 3.58 9 0.40  3.14 6 0.52  1.91 3 0.64  1.40 2 0.70 
Female 137 / 86 6.4 Hyper and pre-diabetic 1.24 4 0.31  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 125 / 74 5.3 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 115 / 78 5.6 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 125 / 76 5.8 Normal and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 148 / 75 5.7 Hyper and pre-diabetic 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Female 124 / 86 5.2 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 120 / 69 5.2 Normal and optimal 1.13 3 0.38  1.13 3 0.38  0.00 0 0.00  0.00 0 0.00 
Female 117 / 70 4.8 Normal and optimal 4.54 14 0.32  3.38 8 0.42  1.06 2 0.53  0.00 0 0.00 
Female 127 / 81 5.3 Hyper and optimal 1.60 4 0.40  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Female 108 / 66 5 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 120 / 72 5.4 Normal and optimal 1.67 4 0.42  1.67 4 0.42  0.51 1 0.51  0.00 0 0.00 
Female 123 / 81 5.6 Hyper and optimal 3.58 9 0.40  3.14 6 0.52  1.91 3 0.64  1.40 2 0.70 
Female 140 / 81 5.8 Hyper and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 117 / 74 5.1 Normal and optimal 2.93 7 0.42  2.59 5 0.52  1.28 2 0.64  1.28 2 0.64 
Female 115 / 71 5.4 Normal and optimal 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 117 / 66 6.1 Normal and pre-diabetic 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 113 / 70 5.4 Normal and optimal 1.37 4 0.34  1.21 3 0.40  0.00 0 0.00  0.00 0 0.00 
Male 132 / 82 5.6 Hyper and optimal 3.43 8 0.43  3.01 6 0.50  1.36 2 0.68  1.36 2 0.68 
Female 105 / 73 5.2 Normal and optimal 0.99 3 0.33  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 138 / 85 5.1 Hyper and optimal 4.11 11 0.37  3.33 7 0.48  1.71 3 0.57  1.20 2 0.60 
Female 106 / 72 5.1 Normal and optimal 1.49 3 0.50  1.49 3 0.50  0.67 1 0.67  0.67 1 0.67 
Male 135 / 90 5.5 Hyper and optimal 1.76 5 0.35  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Male 125 / 80 5.5 Hyper and optimal 1.16 3 0.39  1.16 3 0.39  0.00 0 0.00  0.00 0 0.00 
Male 134 / 82 5.6 Hyper and optimal 1.34 3 0.45  1.34 3 0.45  0.52 1 0.52  0.00 0 0.00 
Female 115 / 77 5.5 Hyper and optimal 2.70 6 0.45  2.48 5 0.50  1.31 2 0.66  1.31 2 0.66 
Female 127 / 73 5.7 Hyper and pre-diabetic 1.64 4 0.41  1.64 4 0.41  0.51 1 0.51  0.00 0 0.00 
Female 112 / 71 5.2 Normal and optimal 2.57 7 0.37  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Female 126 / 75 5.7 Hyper and pre-diabetic 1.13 3 0.38  1.13 3 0.38  0.00 0 0.00  0.00 0 0.00 
Female 118 / 73   Normal and  1.13 3 0.38  1.13 3 0.38  0.00 0 0.00  0.00 0 0.00 
Female 119 / 72 4.7 Normal and optimal 1.13 3 0.38  1.13 3 0.38  0.00 0 0.00  0.00 0 0.00 
Female 143 / 93 5.4 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 120 / 69 5.1 Hyper and optimal 3.25 9 0.36  2.82 6 0.47  1.22 2 0.61  1.22 2 0.61 
Female 112 / 76 5.9 Hyper and pre-diabetic 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Male 123 / 78 5.7 Normal and pre-diabetic 1.47 4 0.37  1.47 4 0.37  0.00 0 0.00  0.00 0 0.00 
Male 123 / 73 5.5 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 118 / 75 5.4 Normal and optimal 2.82 7 0.40  2.56 5 0.51  1.74 3 0.58  1.24 2 0.62 
Male 151 / 95 6.1 Hyper and pre-diabetic 4.11 11 0.37  3.45 7 0.49  1.80 3 0.60  1.29 2 0.65 
Male 123 / 74 5.9 Normal and pre-diabetic 2.09 5 0.42  1.93 4 0.48  1.11 2 0.55  0.00 0 0.00 
Female 108 / 69 5.2 Normal and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 121 / 65 5.9 Normal and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 127 / 81 5.4 Hyper and optimal 1.96 7 0.28  1.26 3 0.42  0.00 0 0.00  0.00 0 0.00 
Female 123 / 78 5 Hyper and optimal 2.89 7 0.41  2.55 5 0.51  1.24 2 0.62  1.24 2 0.62 
Female 110 / 67 5.1 Normal and optimal 2.93 7 0.42  2.59 5 0.52  1.28 2 0.64  1.28 2 0.64 
Female 112 / 74 5.2 Normal and optimal 1.78 5 0.36  1.44 3 0.48  0.62 1 0.62  0.62 1 0.62 
Male 129 / 82 5.7 Hyper and pre-diabetic 2.73 7 0.39  2.47 5 0.49  1.24 2 0.62  1.24 2 0.62 
Male 130 / 83 5 Hyper and optimal 3.21 8 0.40  2.94 6 0.49  1.24 2 0.62  1.24 2 0.62 
Male 153 / 99 5.1 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 107 / 70 5 Normal and optimal 2.53 7 0.36  2.11 5 0.42  0.00 0 0.00  0.00 0 0.00 
Female 146 / 85 5.4 Hyper and optimal 2.32 6 0.39  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Male 144 / 85 7.4 Hyper and diabetic 2.57 7 0.37  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Male 117 / 77 5.8 Normal and pre-diabetic 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Male 125 / 76 5.5 Normal and optimal 2.14 6 0.36  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Male 120 / 83 5.6 Hyper and optimal 4.11 11 0.37  3.33 7 0.48  1.71 3 0.57  1.20 2 0.60 
Female 111 / 72 5.3 Normal and optimal 3.99 10 0.40  3.55 7 0.51  1.91 3 0.64  1.40 2 0.70 
Female 122 / 63 5.4 Hyper and optimal 2.06 6 0.34  1.65 4 0.41  0.00 0 0.00  0.00 0 0.00 
Female 121 / 69 5.3 Hyper and optimal 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Female 139 / 82 5.7 Hyper and pre-diabetic 2.99 7 0.43  2.62 5 0.52  1.30 2 0.65  1.30 2 0.65 
Female 116 / 70 5.6 Normal and optimal 1.56 5 0.31  1.26 3 0.42  0.00 0 0.00  0.00 0 0.00 
Male 109 / 65 5.4 Normal and optimal 3.94 12 0.33  3.28 8 0.41  0.61 1 0.61  0.61 1 0.61 
Male 127 / 81 5.9 Hyper and pre-diabetic 2.57 7 0.37  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Male 125 / 77 5.4 Normal and optimal 1.28 3 0.43  1.28 3 0.43  0.00 0 0.00  0.00 0 0.00 
Female 118 / 75 5.2 Hyper and optimal 2.66 7 0.38  2.25 5 0.45  0.60 1 0.60  0.60 1 0.60 
Male 124 / 77 5.1 Normal and optimal 2.66 7 0.38  2.25 5 0.45  0.60 1 0.60  0.60 1 0.60 
Male 121 / 74 5.2 Normal and optimal 2.28 5 0.46  2.12 4 0.53  1.29 2 0.65  1.29 2 0.65 
Male 147 / 94 5.6 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 118 / 78 5.9 Normal and pre-diabetic 2.36 5 0.47  2.14 4 0.53  1.31 2 0.66  1.31 2 0.66 
Male 125 / 82 5.7 Hyper and pre-diabetic 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 127 / 77 5.4 Normal and optimal 3.96 12 0.33  3.24 8 0.40  0.61 1 0.61  0.61 1 0.61 
Male 135 / 88 5.4 Hyper and optimal 2.82 7 0.40  2.56 5 0.51  1.74 3 0.58  1.24 2 0.62 
Male 121 / 85 6.6 Hyper and diabetic 1.30 5 0.26  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 124 / 73 5.3 Normal and optimal 2.24 5 0.45  1.99 4 0.50  1.17 2 0.59  0.66 1 0.66 
Male 130 / 74 5.5 Hyper and optimal 2.66 8 0.33  2.18 5 0.44  0.53 1 0.53  0.00 0 0.00 
Female 116 / 68 6.9 Normal and diabetic 3.62 9 0.40  3.19 6 0.53  1.96 3 0.65  1.96 3 0.65 
Male 124 / 80 6.1 Hyper and pre-diabetic 2.53 7 0.36  2.11 5 0.42  0.00 0 0.00  0.00 0 0.00 
Male 156 / 95 5.8 Hyper and pre-diabetic 1.81 6 0.30  1.22 3 0.41  0.00 0 0.00  0.00 0 0.00 
Male 129 / 86 6 Hyper and pre-diabetic 4.54 14 0.32  3.38 8 0.42  1.06 2 0.53  0.00 0 0.00 
Female 125 / 79 5.7 Hyper and pre-diabetic 2.89 7 0.41  2.55 5 0.51  1.24 2 0.62  1.24 2 0.62 
Female 123 / 78 6 Hyper and pre-diabetic 3.67 9 0.41  3.24 6 0.54  2.01 3 0.67  2.01 3 0.67 
Male 112 / 71 5.1 Normal and optimal 1.24 4 0.31  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Male 141 / 93 5.9 Hyper and pre-diabetic 3.99 10 0.40  3.55 7 0.51  1.91 3 0.64  1.40 2 0.70 
Female 130 / 84 5.5 Hyper and optimal 5.20 13 0.40  4.72 10 0.47  2.38 4 0.60  1.29 2 0.64 
Male 113 / 72 5.5 Normal and optimal 1.85 6 0.31  1.22 3 0.41  0.00 0 0.00  0.00 0 0.00 
Male 128 / 77 6.3 Normal and pre-diabetic 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 125 / 77 5.6 Normal and optimal 2.82 7 0.40  2.56 5 0.51  1.74 3 0.58  1.24 2 0.62 
Female 119 / 74 5.3 Normal and optimal 1.76 5 0.35  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Female 135 / 74 5.3 Hyper and optimal 0.82 2 0.41  0.82 2 0.41  0.00 0 0.00  0.00 0 0.00 
Female 104 / 66 5.3 Normal and optimal 1.76 5 0.35  1.43 3 0.48  0.61 1 0.61  0.61 1 0.61 
Male 113 / 75 6.2 Normal and pre-diabetic 2.32 6 0.39  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
Female 114 / 67 5.1 Normal and optimal 3.98 13 0.31  2.83 7 0.40  0.51 1 0.51  0.00 0 0.00 
Male 117 / 69 5.4 Normal and optimal 2.32 6 0.39  2.06 4 0.52  1.24 2 0.62  1.24 2 0.62 
 
In this table, several identified and calculated phenotypical and genetic parameters for each participant are listed. The MutPred mutational load 
(Mut. load) and MutPred adjusted load (Adj. load) as well as the number of variants (Num of var) for each participant is given, when all variants 
are considered or when only variants with MutPred pathogenicity scores above a specified threshold (0.3, 0.5 or 0.6) are considered. 24 h 
ABPM, 24 hour ambulatory blood pressure monitoring. Normotensive and hypertensive classifications are based on 24 hour systolic and 
diastolic ambulatory blood pressure measurements with hypertensive participants being those with 24 h systolic ABPM above 130 mmHg for 
males, 125 mmHg for females, and/or 24 h diastolic ABPM above 80 mmHg for males, 75 mmHg for females. HbA1c, Glycated haemoglobin is 
measured to calculate the three month average plasma glucose concentration. HbA1c measurements were used to classify participants as having 
either optimal blood glucose levels (HbA1c < 5.7%), being pre-diabetic (HbA1c from 5.7% to 6.4%) or diabetic (HbA1c > 6.4%). MutPred, a 
pathogenicity score assigned to a variant using the MutPred program (mutpred.mutdb.org/about.html). 
  
Table S2. Top twenty-five variants with the highest number of instances in the SABPA cohort data set 
Variant MutPred score Number of 
instances in 
cohort total 
Number of 
instances in 
haplogroup L 
participants 
Number of 
instances in 
haplogroup MN 
participants 
Number of 
instances on 
Phylotree 
Present in 
macro-
haplogroup L 
on Phylotree 
Present in 
macro-
haplogroup MN 
on Phylotree 
4232C 0.609 87 78 8 6 Yes Yes 
5460A 0.505 58 52 6 43 Yes Yes 
4216C 0.611 39 0 39 13 Yes Yes 
4917G 0.628 25 1 24 6 No Yes 
11172G 0.630 21 21 0 3 Yes Yes 
14798C 0.609 14 0 14 5 No Yes 
14000A 0.552 11 9 2 4 Yes Yes 
14178C 0.516 11 11 0 5 Yes Yes 
13789C 0.576 10 10 0 2 Yes Yes 
13886C 0.571 8 8 0 1 Yes No 
15257A 0.785 8 0 8 3 No Yes 
9098C 0.685 8 0 8 5 Yes Yes 
13780G 0.606 7 0 7 1 No Yes 
15812A 0.518 7 1 6 3 Yes Yes 
8618C 0.641 7 7 0 4 Yes Yes 
10114C 0.603 6 6 0 1 Yes No 
10128A 0.609 6 6 0 1 Yes No 
15312C 0.530 6 6 0 1 Yes No 
15617A 0.714 6 3 3 3 Yes Yes 
6150A 0.676 6 6 0 2 Yes Yes 
6723A 0.653 6 6 0 1 Yes No 
7119A 0.520 6 6 0 2 Yes Yes 
13129T 0.850 5 5 0 2 Yes Yes 
14334T 0.501 5 0 5 0 No No 
3434G 0.577 5 5 0 3 Yes Yes 
 
In this table, a description is given for variants with MutPred scores above 0.5 that have the most number of instances in the SABPA cohort data 
set. The MutPred score is given for each variants. The number of instances in the entire cohort, in the haplogroup L participants, and in the 
haplogroup MN participants are also given. Finally, the number of times a variant appears as a haplogroup defining variant on Phylotree 
(http://www.phylotree.org) is given, and whether a variant defines haplogroups within macro-haplogroup L or macro-haplogroup MN. Variants 
that only define either macro-haplogroup L or macro-haplogroup MN lineages, are shown in bold. MutPred: a pathogenicity score assigned to a 
variant using the MutPred program (mutpred.mutdb.org/about.html).  
Gender Mean 24 hour systolic 
ambulatory blood 
pressure measurement
Mean 24 hour diastolic 
ambulatory blood 
pressure measurement
HbA1C% (blood 
glucose 
measurement)
Consensus 
variants        
→
Male 147 102 10.1 719A 750G
Male 140 84 5.5 721C 750G
Female 117 75 5.7 597T 750G
Male 162 96 6.3 597T 750G
Female 160 98 5.7 750G 769A
Female 116 78 5.3 750G 769A
Female 151 78 5.7 750G 769A
Male 114 77 6.4 750G 769A
Female 110 64 5 750G 769A
Female 121 73 5.4 597T 750G
Female 144 90 5.5 597T 750G
Female 124 74 5.7 750G 769A
Female 145 89 6.1 750G 769A
Male 124 79 6 750G 1438G
Male 136 83 6.3 750G 769A
Female 123 73 5.8 750G 769A
Female 144 84 5.7 719A 750G
Female 131 71 5.7 597T 750G
Male 148 94 9.5 597T 709A
Female 120 70 6.3 597T 750G
Male 126 90 5.5 719A 750G
Male 145 93 6.1 750G 769A
Female 129 78 5.3 721C 750G
Male 154 94 6.2 750G 769A
Male 144 92 5.9 750G 769A
Female 113 73 5.4 597T 750G
Male 122 72 6.1 750G 769A
Female 130 82 5.5 750G 769A
Female 130 85 5.6 750G 769A
Male 130 84 5.5 719A 750G
Female 117 80 5.3 750G 769A
Female 111 72 5.2 750G 769A
Female 129 86 5.5 750G 769A
Female 126 81 5.6 750G 1438G
Female 111 73 5.5 750G 769A
Female 137 78 6.2 719A 750G
Female 119 79 5.4 719A 750G
Male 122 75 6 719A 750G
Male 154 103 6.8 750G 769A
Female 127 79 5.8 597T 750G
Female 122 68 5.2 750G 1438G
Male 131 87 5.5 750G 1438G
Supplementary variants
